Patients around the globe are benefiting from a revolution in pharmaceutical and diagnostics innovation. The traditional medicines paradigm of “one-pill-for-all” is rapidly shifting towards a much more tailored approach to “precision medicines” where therapies are targeted to those patients who will specifically benefit from them.
These more efficient and effective treatment approaches can improve patient health outcomes and enhance disease management. Governments will need to build robust public testing infrastructure if patients are to fully realize these benefits. This policy note proposes some core principles to address implementation considerations for further collaborative discussion.